Pfizer Org chart
This Pfizer org chart highlights the company’s organizational structure and leadership team, including key executives such as Albert Bourla (Chairman & CEO) , Chris Boshoff (Chief Oncology Officer) , and Anil Argilla (President, Emerging Markets Asia) . It provides a clear overview of the leadership team’s roles and how they work together to achieve organizational goals and ensure effective management across all functions.
For CEO/executive salary details, click here.
Pfizer Leadership Team
Executives
Profile Summary
Albert Bourla
Chairman & CEO
As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose: Breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health. During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the Pfizer’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions. Previously, from February 2016 to December 2017, Albert served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of Pfizer’s medicines, and ensuring broader business model innovation. From January 2014 to January 2016, Albert served as Group President of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in Oncology and expanding the Company’s leadership in Vaccines. Albert was President and General Manager of Pfizer’s Established Products business from 2010-2013, leading the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio, (including legacy brands and generics). He began his Pfizer career in 1993 in the Animal Health Division as Technical Director of Greece. He held positions of increasing responsibility within Animal Health across Europe, before moving to Pfizer’s New York Global Headquarters in 2001. From there, Albert went on to assume a succession of leadership roles within the Animal Health Division, including US Group Marketing Director (2001-2004), Vice President of Business Development and New Products Marketing (2004-2006), and Area President of Animal Health Europe, Africa and the Middle East (2006-2009). In 2009, he assumed additional responsibilities for the Asia and Pacific regions. Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In 2020, he was ranked as America’s top CEO in the Pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of The Partnership for New York City, a vice president of the International Federation of Pharmaceutical Manufacturers & Associations, a director on multiple boards – Pfizer, Inc., The Pfizer Foundation, PhRMA, and Catalyst – and a trustee of the United States Council for International Business. In addition, Albert is a member of the Business Roundtable and the Business Council.
Chris Boshoff
Chief Oncology Officer
Chris Boshoff is Chief Oncology Officer at Pfizer.
Anil Argilla
President, Emerging Markets Asia
Anil Argilla is an experienced professional in the pharmaceutical and human resources sectors with a strong background in leadership roles. Currently serving as the President of Emerging Markets Asia at Pfizer, Anil has held various key positions including Cluster Head for Mid-size Markets and Head of Emerging Markets Asia within Pfizer Biopharma. Prior to Pfizer, Anil worked as VP of Human Resources at NRB Bearings, a Principal Consultant at ECS, and held HR and executive roles at Eicher and Crompton Greaves. Anil holds an MPM in Business Management from Symbiosis Institute of Business Management and a B.Com in Commerce from Osmania University.
Mikael Dolsten
Chief Scientific Officer & President, WW Research, Development & Medical
Mikael Dolsten focuses on advancing Pfizer’s scientific breakthrough leadership in small-molecule medicines, biotherapeutics, gene therapies and vaccines. He is a member of the Executive Leadership Team and the company’s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities. Mikael leads the Worldwide Research, Development and Medical (WRDM) organization at Pfizer, which is responsible for the development of all compounds through proof of concept, and provides pharmaceutical sciences, safety and medical support to the entire R&D pipeline and all marketed medicines and vaccines. WRDM comprises all Pfizer research units, including Oncology, Internal Medicine, Inflammation & Immunology, Vaccines and Rare Disease, as well as the Centers for Therapeutic Innovation. The Vaccines R&D team leads scientific efforts from discovery through registration of novel vaccines. Mikael also has worldwide responsibility for Pfizer’s medical, safety and external R&D innovation, as well as science-based teams in pharmaceutical sciences, drug safety R&D, and large and small molecule discovery and development. Prior to joining Pfizer in 2009, Mikael was President of Wyeth Research, where he led scientists involved in all R&D/Medical activities across the US, Europe and Asia. Before that, Mikael served as Executive Vice President and Head of Worldwide Research for Boehringer Ingelheim from 2003-2008. Mikael earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden, where he was Adjunct Professor in Tumor Immunology and was recently appointed Visiting Professor to advice on science and technology strategies. He serves on the PhRMA Research & Development Leadership Forum as well as on the PhRMA Foundation Board of Directors. He is a member of the board of Karyopharm Therapeutics and of Research! America. Additionally, Mikael is a member of the Board of Overseers for the Scripps Research Institute and a Foreign Member of The Royal Swedish Academy of Engineering Sciences. Since 2014, Mikael has co-chaired the Accelerating Medicine Partnership with National Institutes of Health (NIH) Director Francis S. Collins. Mikael advised the Obama Administration on regulatory and drug development issues as well as then Vice President Biden’s Cancer Moonshot Initiative to accelerate cancer research. Through 2019, Mikael was a council member of the Government-University-Industry Research Roundtable. Mikael is a named inventor on several patents and has published approximately 150 articles in international journals, with contributions in molecular cell biology, immunology and oncology.
Previous or Current Companies (Board, Advisor, Employer)
Boehringer Ingelheim
Lund University
OrbiMed
AstraZeneca
Andrew Baum
Chief Strategy & Innovation Officer & EVP
Andrew Baum is Chief Strategy & Innovation Officer & EVP at Pfizer.
Previous or Current Companies (Board, Advisor, Employer)
Rady Johnson
EVP, Chief Compliance, Quality & Risk Officer
Rady Johnson is Executive Vice President and Pfizer’s Chief Compliance, Quality and Risk Officer. He has overall responsibility for the company's global compliance program, Regulatory Quality Assurance organization, global security efforts, and Office of the Ombuds. Since joining Pfizer in 1994, Rady has led the Regulatory Law practice group as well as the Corporate Regulatory and Healthcare Law Audit functions, established the Legal Division’s Global Products Counsel practice group, and served as Senior Vice President and Associate General Counsel for the innovative segments of Pfizer’s Worldwide Biopharmaceuticals Business. Prior to joining the company, Rady was in private practice in Washington, DC, with the law firm of Hogan & Hartson, where he was a member of their food and drug law practice. Previously, Rady was a Certified Public Accountant specializing in the healthcare and hospitality industries for Arthur Anderson. He is a graduate of the University of Richmond and the Georgetown University Law Center. Rady was recognized by the Ethisphere Institute in 2015 as an Attorney Who Matters for his work in helping to “pioneer a corporate and industry-wide legacy of ethics and integrity.” He chairs the International Federation of Pharmaceutical Manufacturers & Associations' Ethics & Business Integrity Committee, serves on the board of directors of the Pro Bono Partnership and the Citizens Crime Commission of New York City, is an adjunct professor at the University of Connecticut School of Law, and is very active in many local charities and organizations in his hometown of Westport, CT.
Payal Sahni
EVP & Chief People Experience Officer
Payal Sahni is Executive Vice President, Chief People Experience Officer, responsible for Pfizer’s global talent strategy, diversity and inclusion, total rewards and colleague experience. In her prior role, Payal was the Senior Vice President, Human Resources, for Pfizer Biopharmaceuticals Group, leading the HR strategy for seven business units, as well as for the Corporate Affairs, Legal, Compliance and Chief Business Office functions. Payal joined Pfizer Human Resources in 1997. Since then, she has held a number of Regional and Global HR Business Partner roles supporting the business around the world and has led the Talent Organization for Pfizer Global Supply. In addition, Payal has spearheaded numerous transformations as Pfizer evolved its business structure and has been instrumental in managing HR strategy for several mergers and acquisitions. Payal holds a Bachelor of Arts in Psychology from Rider University and a Master of Arts in Psychology from Fairleigh Dickinson University.
Aamir Malik
Chief US Commercial Officer & EVP
Aamir Malik is Executive Vice President, Chief U.S. Commercial Officer, Pfizer Inc. Aamir is a member of Pfizer’s Executive Leadership Team (ELT). He leads the U.S. Commercial business, which consists of U.S. Primary and Specialty Care, as well as Global Value and Access, Global Medical Affairs, and Global Chief Marketing Office organizations. Previously Aamir served as the Executive Vice President, Chief Business Innovation Officer, responsible for the company’s strategy, business development, commercial development, portfolio management, pipeline prioritization, and formation of new business ventures. Prior to joining Pfizer, Aamir was the Managing Partner of McKinsey & Company’s United States operations and previously led the firm’s Global Pharmaceutical and Medical Products Practice. In his 25 years at McKinsey, Aamir developed innovative growth strategies, guided mergers and acquisitions, and implemented high-impact programs to improve patients’ lives and transform performance for life science companies. He has advised many Boards, CEOs, and top management teams in the life science space. Aamir earned a Bachelor of Science in finance from Indiana University and currently serves on the University’s Kelly School of Business Dean’s Council. He is an active advocate for bettering the lives of people with food allergies and has lived and worked globally, including in the United States, Europe, Asia, Latin America, and Africa.
Previous or Current Companies (Board, Advisor, Employer)
McKinsey & Company
Mike McDermott
EVP & Chief Global Supply Officer
As Chief Global Supply Officer, Executive Vice President, Mike McDermott leads all of Pfizer’s internal and external manufacturing and supply chain activities. Mike and the Pfizer Global Supply (PGS) team work to ensure uninterrupted supply for Pfizer’s entire product portfolio, which includes hundreds of medicines and vaccines – more than 38 billion doses each year. The PGS network includes approximately 30,000 colleagues and contractors and 39 Pfizer global manufacturing sites. Recent highlights include the rapid ramp-up of manufacturing and global distribution of the Pfizer-BioNTech COVID-19 vaccine; ongoing efforts to enhance COVID-19 vaccine production and distribution processes; and the expedited production of Pfizer’s novel COVID-19 oral antiviral. Mike has more than 30 years of experience in the pharmaceutical industry and has held positions in all aspects of supply operations as well as in Marketing and Finance. He joined Wyeth in 1989 as a Project Engineer in Pearl River, New York. Mike returned to Pearl River in 2003 as the site’s Managing Director for Vaccines manufacturing and was elevated to the role of Vice President of Site Operations in 2007. With Pfizer’s acquisition of Wyeth in 2009, Mike became leader of the Consumer Healthcare Operating Unit and then was named Vice President of the Biotechnology Unit in 2012. In 2014, Mike became Vice President of Global Supply Chain, overseeing internal and external supply as well as distribution. He was named President of PGS in 2018 and assumed his current role in January 2022. A passionate advocate for Diversity, Equity and Inclusion, Mike served on the Board of People to People, a non-profit organization that helps under-served people, for 10 years, and has enacted impactful changes to increase diversity within PGS. Mike, his wife Katie and their five daughters, of whom Mike is incredibly proud, are all committed to community engagement and social action. Mike has Bachelor of Science and Master of Science degrees in Industrial Engineering from the New Jersey Institute of Technology (NJIT) in Newark, New Jersey. He has been an adjunct professor at NJIT and was named a distinguished alumnus. Mike serves on the Executive Committee of the National Association of Manufacturers and is a member of the Pharmaceutical Manufacturers Forum as well.
Alexandre De Germay
Chief International Commercial Officer & EVP
Alexandre de Germay currently serves as the Chief International Commercial Officer at Pfizer since December 2023 and as the Chief Executive Officer at Laboratoires Majorelle since October 2021. Previously, Alexandre held various senior leadership roles at Sanofi from June 2016 to October 2021, including Senior Vice President Global Head of Cardiovascular and Established Products Franchise and Head of General Medicines Business. Alexandre's extensive career at Pfizer from June 1995 to May 2016 encompassed multiple positions such as Regional President Asia-Pacific, Vice President of Global Brands, and Senior Director of Worldwide Commercial Lead for Urology, Gynaecology, and Sexual Health, among others.
Previous or Current Companies (Board, Advisor, Employer)
Sanofi
Wenjin Wang
Executive Director
Wenjin Wang is Executive Director at Pfizer.
Berta Rodriguez-Hervas
Chief AI & Analytics Officer, Senior Vice President
Berta Rodriguez-Hervas is an accomplished professional in the field of artificial intelligence and machine learning, currently serving as the Chief AI & Analytics Officer at Pfizer. Prior experience includes holding the position of Vice President of Artificial Intelligence, Algorithms and ML Ops at Stellantis and serving as a Senior SW Engineering Manager/Principal Scientist focused on Computer Vision and Deep Learning at NVIDIA. Berta also contributed to advancements in Autopilot Computer Vision as both a Machine Learning Manager and Senior Machine Learning Engineer at Tesla. Academic credentials include a Doctor of Philosophy (PhD) in Electrical and Computer Engineering from The University of Texas at El Paso and studies at Michigan State University.
Lidia Fonseca
EVP & Chief Digital & Technology Officer
Lidia Fonseca is the Executive Vice President, Chief Digital and Technology Officer at Pfizer, responsible for the enterprise-wide digital strategy. Lidia leads all digital, data and technology products and solutions across the company, including digitizing drug discovery, clinical development, manufacturing, distribution and commercial. Her team accelerates innovation at Pfizer by enhancing operational processes through automation and robotics, and delivering powerful insights with data, advanced analytics, and artificial intelligence (AI) for better and faster decision-making. She is also responsible for Pfizer Learning and Development and Business Process Excellence. As the intersection of Digital and healthcare expands, Lidia is spearheading the effort to improve patient health outcomes through innovative digital health, medicines, and diagnostics products. Under her leadership, Pfizer launched the Digital Companion™, a suite of digital products and solutions to deepen engagement between patients and physicians. She is also leading the effort to introduce AI-powered predictive algorithms to help disease suspicion, treatment optimization and adherence. Lidia led the Digital team in Pfizer’s critical efforts to help accelerate the development of a COVID-19 vaccine, Cominarty, in less than one year, as well as the oral treatment, Paxlovid, driving innovations across the entire value chain from research to the clinical trials, to manufacturing, distribution and patient engagement. Under her leadership, Pfizer has automated over 90 percent of 100 million transactional processes across the company and Lidia’s team launched the Pfizer Learning Academy, providing learning, training, and development for all Pfizer employees. Lidia has 20+ years of experience in the healthcare industry. In her prior role, Lidia was the Senior Vice President and CIO at Quest Diagnostics, the world’s leading provider of diagnostic information services serving one in three American adults each year, and half the physicians and hospitals in the U.S. She was responsible for technology, informatics and digital solutions. She led the effort to create Quest's innovative Quanum Solutions brand of healthcare IT and data analytics offerings that deliver critical insights to improve quality outcomes and patient care while lowering costs. Lidia has received numerous awards and accolades, including being named on the 2022 Forbes CIO Next List recognizing the top 50 tech leaders who are redefining the CIO role and driving game-changing innovation. She was named to the 50 Most Powerful Latinas in 2020 and 2021 by the Association of Latino Professionals for America. In 2022, Pfizer won multiple awards in digital manufacturing including the CIO 100 award for digital innovation in manufacturing, the Manufacturing Leadership Award for digital supply chain innovation from the Manufacturing Leadership Council, and Gartner’s Supply Chain Breakthrough of the Year Award. She was named 2020 Healthcare Influencer and 2019 Healthcare Transformer by Medical, Marketing & Media and received the 2017 Forbes CIO Innovation Award that recognizes CIOs who lead revenue enhancing innovation efforts. Lidia is a member of the Board of Directors of Medtronic (NYSE: MDT), Tegna, Inc. (NYSE: TGNA), and the U.S.-Japan Business Council. She was previously a member of the Board of Directors of Gannet, Inc. (NYSE: GCI) from 2014-2017 and Q2 Solutions, a joint venture between Quest Diagnostics and IQVIA, from 2016 to 2018. She earned a bachelor’s degree from the University of California, Berkeley and an MBA and Master Business Informatics from Rotterdam School of Management, Erasmus Graduate School of Business.
Previous or Current Companies (Board, Advisor, Employer)
LabCorp
Philips
Quest Diagnostics
Doug Lankler
EVP, General Counsel
Doug Lankler joined Pfizer in 1999 and currently serves as general counsel. Prior to being named general counsel, Doug was Pfizer's chief compliance and risk officer, a role he assumed in 2006. Prior to joining the company, Doug was with the United States Department of Justice as an Assistant U.S. Attorney in the Southern District of New York. Doug was a recipient of the United States Attorney General's Distinguished Service Award. Doug graduated from the State University of New York at Albany and Cornell Law School.
Previous or Current Companies (Board, Advisor, Employer)
Simpson Thacher & Bartlett
Sally Susman
EVP & Chief Corporate Affairs Officer
Sally Susman is Executive Vice President and Chief Corporate Affairs Officer at Pfizer. She is vice chair of the Pfizer Foundation and co-chair of Pfizer’s Political Action Committee. Sally leads engagement with all of Pfizer’s external stakeholders overseeing communications, corporate responsibility, global policy, government relations, investor relations and patient advocacy. Before joining Pfizer in 2007, Sally held several senior communications and government relations roles at Estée Lauder Companies and the American Express Company. Earlier in her career, she spent eight years in government service focused on international trade issues. Sally serves on the board of UL Solutions, a global leader in applied safety science, and as co-chair of the board of The International Rescue Committee. She is also a member of the Council on Foreign Relations.
Previous or Current Companies (Board, Advisor, Employer)
David M. Denton
EVP & CFO
Dave M. Denton is the Chief Financial Officer and Executive Vice President for Pfizer. Dave is a member of Pfizer’s Executive Leadership Team (ELT), providing strategic global financial leadership. Dave leads the corporate finance functions including audit, treasury, tax, insurance, operations planning and analysis (OP&A), corporate controllership, and business finance and analytics. Dave has more than 25 years of finance and operational expertise, including more than 20 years in the healthcare sector. As a result, he brings to Pfizer a unique perspective on the role of payers, the needs of patients, and the rapidly evolving healthcare landscape. Prior to joining Pfizer, Dave was the CFO and Executive Vice President of Lowe’s Companies Inc. He joined Lowes in 2018 and was responsible for all of Lowe’s financial functions and processes. This includes corporate finance and treasury, strategy, real estate, accounting, tax, internal audit and risk management. Before joining Lowe's, he served as executive vice president and CFO of CVS Health, where he was responsible for all aspects of financial planning and management. Dave played a key role in CVS’s transformational journey from a retail pharmacy to the health solutions company it is today and led the full integration of Caremark into CVS. In December 2017, he played a pivotal role in one of the largest healthcare transactions in history when CVS acquired Aetna - structuring and negotiating the terms and financing for the transaction. Before being named the CFO of CVS Health, Dave held several leadership roles at CVS, including Senior Vice President and Controller/Chief Accounting Officer. Prior to CVS, Dave was with the management consulting firm of Deloitte Touche Tohmatsu. Dave earned a bachelor's degree in business administration from Kansas State University and an MBA from the Babcock Graduate School of Management at Wake Forest University. He serves on the board of Tapestry, Inc.
Previous or Current Companies (Board, Advisor, Employer)
Deloitte
Iona Munjal
Vice President
Iona Munjal serves as the Executive Director at Pfizer and has previously held the position of Director. Iona Munjal is a medical doctor, having worked at Montefiore Medical Center. Academic credentials include a degree in Biology from Georgetown University, earned between August 1997 and May 2001.
Previous or Current Companies (Board, Advisor, Employer)
Albert Einstein College of Medicine
